癌症治疗中的周期性禁食模拟饮食：临床前和临床证据。
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence.
发表日期：2024 Aug 06
作者：
Claudio Vernieri, Francesca Ligorio, Debu Tripathy, Valter D Longo
来源：
Cell Metabolism
摘要：
在临床前肿瘤模型中，周期性禁食和模拟禁食饮食（FMD）可产生抗肿瘤作用，当与多种标准抗癌治疗相结合时，这些作用会产生协同作用，同时保护正常组织免受治疗引起的不良事件的影响。最近，1/2期临床试验结果表明，循环FMD是安全、可行的，并且对不同肿瘤类型的患者具有积极的代谢和免疫调节作用，从而为更大规模的临床试验研究FMD在不同肿瘤类型中的抗癌活性铺平了道路。临床背景。在这里，我们回顾了禁食/口蹄疫抗肿瘤作用的肿瘤细胞自主和免疫系统介导的机制，并批判性地讨论了新的代谢干预措施，这些干预措施可以与营养饥饿协同作用，以增强其抗癌活性并预防或逆转肿瘤耐药性，同时最大限度地减少肿瘤耐药性。对患者的毒性。最后，我们重点介绍了 FMD 方法与标准抗癌策略以及临床试验设计和实施策略相结合的未来潜在应用。版权所有 © 2024 Elsevier Inc. 保留所有权利。
In preclinical tumor models, cyclic fasting and fasting-mimicking diets (FMDs) produce antitumor effects that become synergistic when combined with a wide range of standard anticancer treatments while protecting normal tissues from treatment-induced adverse events. More recently, results of phase 1/2 clinical trials showed that cyclic FMD is safe, feasible, and associated with positive metabolic and immunomodulatory effects in patients with different tumor types, thus paving the way for larger clinical trials to investigate FMD anticancer activity in different clinical contexts. Here, we review the tumor-cell-autonomous and immune-system-mediated mechanisms of fasting/FMD antitumor effects, and we critically discuss new metabolic interventions that could synergize with nutrient starvation to boost its anticancer activity and prevent or reverse tumor resistance while minimizing toxicity to patients. Finally, we highlight potential future applications of FMD approaches in combination with standard anticancer strategies as well as strategies to implement the design and conduction of clinical trials.Copyright © 2024 Elsevier Inc. All rights reserved.